Key result
Having three elevated biomarkers (cTnI, NT-proBNP, hsCRP) increased the risk of major adverse cardiac events by 23.4-fold compared to zero elevated biomarkers in advanced chronic heart failure.
Why the study?
Does a multimarker approach using cTnI, NT-proBNP, and hsCRP effectively stratify risk for major adverse cardiac events in patients with advanced chronic heart failure?
Cohort (n=152)
Does a multimarker approach using cTnI, NT-proBNP, and hsCRP effectively stratify risk for major adverse cardiac events in patients with advanced chronic heart failure?
Effect estimate: HR 23.4
p-value: p=<0.0001
A multimarker strategy combining cTnI, hsCRP, and NT-proBNP significantly improves risk stratification for adverse events in patients with advanced chronic heart failure.
No takes yet. Share an insight, caveat, or question.
May enhance risk stratification in advanced HF; hypothesis-generating and requires prospective validation before guiding care.
Yin et al. (2007) conducted a cohort in Advanced Chronic Heart Failure (n=152). Multimarker approach (cTnI, NT-proBNP, hsCRP) vs. Zero elevated biomarkers was evaluated on Major adverse cardiac events (cardiac death, requirement for heart transplantation or hospitalization for worsening heart failure) (HR 23.4, p=<0.0001). Having three elevated biomarkers (cTnI, NT-proBNP, hsCRP) increased the risk of major adverse cardiac events by 23.4-fold compared to zero elevated biomarkers in advanced chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: